down arrow

Regulus Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US75915K3095
USD
8.16
0.00 (0.00%)

Jun 26

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.838.35
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Mar 2025)

FII

2.69%

Held by 17 FIIs

DII

48.62%

Held by 41 DIIs

Promoter

13.99%

How big is Regulus Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Regulus Therapeutics, Inc. has a market capitalization of 567.72 million, with net sales of 0.00 million and a net profit of -47.52 million over the last four quarters. The company reported shareholder's funds of 76.41 million and total assets of 84.18 million as of Dec 24.

Market Cap: As of Jun 18, Regulus Therapeutics, Inc. has a market capitalization of 567.72 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Regulus Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -47.52 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 76.41 million and total assets of 84.18 million.

Read More

What does Regulus Therapeutics, Inc. do?

22-Jun-2025

Regulus Therapeutics, Inc. is a biopharmaceutical company focused on developing drugs that target microRNAs for various diseases. It has a market cap of approximately $567.72 million and reported a net profit loss of $10 million in March 2025.

Overview: <BR>Regulus Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 567.72 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.94 <BR>Return on Equity: -68.85% <BR>Price to Book: 8.22<BR><BR>Contact Details: <BR>Address: 10628 Science Center Dr Ste 225, SAN DIEGO CA: 92121-1124 <BR>Tel: 1 858 2026300 <BR>Website: http://www.regulusrx.com/

Read More

Who are in the management team of Regulus Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Regulus Therapeutics, Inc. includes Dr. Stelios Papadopoulos (Independent Chairman), Mr. Joseph Hagan (President and CEO), and several Independent Directors: Dr. David Baltimore, Ms. Kathryn Collier, Mr. Jake Nunn, Dr. William Rastetter, and Dr. Hugh Rosen. This team provides executive leadership and governance for the company.

As of March 2022, the management team of Regulus Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Stelios Papadopoulos, who serves as the Independent Chairman of the Board.<BR>- Mr. Joseph Hagan, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. David Baltimore, who is an Independent Director.<BR>- Ms. Kathryn Collier, who is also an Independent Director.<BR>- Mr. Jake Nunn, serving as an Independent Director.<BR>- Dr. William Rastetter, who is an Independent Director.<BR>- Dr. Hugh Rosen, who is another Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Regulus Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of March 11, 2022, Regulus Therapeutics, Inc. is overvalued with a valuation grade of "does not qualify," indicated by poor financial metrics such as a Price to Book Value of 8.24, negative ROCE of -1237.25%, and underperformance compared to peers, despite a year-to-date stock return of 416.46%.

As of 11 March 2022, the valuation grade for Regulus Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, as evidenced by its Price to Book Value of 8.24 and an EV to Capital Employed ratio of 120.55, which suggests that the market is pricing the company at a premium despite its poor financial performance. Additionally, the negative ROCE of -1237.25% and ROE of -68.85% further highlight the challenges the company faces.<BR><BR>In comparison to its peers, Regulus Therapeutics, Inc. has a less favorable EV to EBITDA ratio of -9.81, while BeyondSpring, Inc. and Aligos Therapeutics, Inc. have ratios of -7.9578 and 0.6671, respectively, indicating that Regulus is underperforming relative to these competitors. Despite its recent strong returns, with a year-to-date stock return of 416.46% compared to the S&P 500's 12.22%, the valuation metrics suggest that the stock is not justified at its current price level.

Read More

Is Regulus Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of May 27, 2025, Regulus Therapeutics, Inc. shows a bullish trend supported by various indicators, despite bearish momentum in the RSI and Dow Theory, and has significantly outperformed the S&P 500 with a year-to-date return of 416.46% compared to 12.22%.

As of 27 May 2025, the technical trend for Regulus Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish signals in the MACD (both weekly and monthly), Bollinger Bands (weekly and monthly), KST (weekly and monthly), and moving averages (daily). However, the RSI indicates bearish momentum on both the weekly and monthly time frames, and Dow Theory shows a bearish signal on the weekly chart with no trend on the monthly.<BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 416.46% compared to the S&P 500's 12.22%, and over the past year, it has returned 300.0% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 534 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

85.78%

stock-summary
Debt Equity

-0.94

stock-summary
Return on Equity

-68.85%

stock-summary
Price to Book

7.74

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
532.56%
0%
532.56%
6 Months
410.0%
0%
410.0%
1 Year
300.0%
0%
300.0%
2 Years
508.96%
0%
508.96%
3 Years
239.15%
0%
239.15%
4 Years
-10.82%
0%
-10.82%
5 Years
11.48%
0%
11.48%

Regulus Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Regulus Therapeutics, Inc. technically bullish or bearish?

As of 27 May 2025, the technical trend for Regulus Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish signals in the MACD (both weekly and monthly), Bollinger Bands (weekly and monthly), KST (weekly and monthly), and moving averages (daily). However, the RSI indicates bearish momentum on both the weekly and monthly time frames, and Dow Theory shows a bearish signal on the weekly chart with no trend on the monthly. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 416.46% compared to the S&P 500's 12.22%, and over the past year, it has returned 300.0% versus the S&P 500's 17.14%....

Read More

Is Regulus Therapeutics, Inc. overvalued or undervalued?

As of 11 March 2022, the valuation grade for Regulus Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, as evidenced by its Price to Book Value of 8.24 and an EV to Capital Employed ratio of 120.55, which suggests that the market is pricing the company at a premium despite its poor financial performance. Additionally, the negative ROCE of -1237.25% and ROE of -68.85% further highlight the challenges the company faces. In comparison to its peers, Regulus Therapeutics, Inc. has a less favorable EV to EBITDA ratio of -9.81, while BeyondSpring, Inc. and Aligos Therapeutics, Inc. have ratios of -7.9578 and 0.6671, respectively, indicating that Regulus is underperforming relative to these competitors. Despite its recent strong returns, with a year-to-date stock return of 416.46% compared to the S&P 500's ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-1.23%
EBIT Growth (5y)
-191.35%
EBIT to Interest (avg)
-30.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.94
Sales to Capital Employed (avg)
0.15
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.24
EV to EBIT
-9.74
EV to EBITDA
-9.81
EV to Capital Employed
120.55
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1237.25%
ROE (Latest)
-68.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bearish
No Trend
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 19 Schemes (34.7%)

Foreign Institutions

Held by 17 Foreign Institutions (2.69%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -12.94% vs -19.72% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.50",
          "val2": "-8.70",
          "chgp": "-20.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.60",
          "val2": "-8.50",
          "chgp": "-12.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -54.67% vs -6.01% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-49.70",
          "val2": "-30.90",
          "chgp": "-60.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.60",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-46.40",
          "val2": "-30.00",
          "chgp": "-54.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-10.50
-8.70
-20.69%
Interest
0.00
0.10
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-9.60
-8.50
-12.94%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -12.94% vs -19.72% in Mar 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-49.70
-30.90
-60.84%
Interest
0.20
0.60
-66.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-46.40
-30.00
-54.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -54.67% vs -6.01% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Regulus Therapeutics, Inc. stock-summary
stock-summary
Regulus Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
Company Coordinates stock-summary
Company Details
10628 Science Center Dr Ste 225 , SAN DIEGO CA : 92121-1124
stock-summary
Tel: 1 858 2026300
stock-summary
http://www.regulusrx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."